Reviewed listing: NASDAQ:LGND · Analysis dated Oct 22, 2026
It has not been confirmed whether the basis of this analysis still holds today. Read it as a dated earlier assessment; it does not establish a current buying opportunity.
How does the company make money?
Ligand finances drug development projects and receives royalties and milestone payments in return. Partners develop and sell the drugs, so Ligand does not sell a single main product of its own.
What supports the business?
Recurring licensing fees rose by around 32% to 48.0 million USD in the second quarter. This is more reliable than a one-time investment gain.
What could improve?
More approved partner products and the XOMA portfolio acquired in July can broaden revenue. But new projects must first earn back their high upfront payments.
How is the stock price assessed?
This assessment refers to the analysis and its quoted price shown here. It is not a live quote or a personal recommendation to buy.
314.78 USD is about 34 times the midpoint of the adjusted full-year earnings forecast. My cautious ceiling is 260 USD; the stock is therefore expensive.
What is the main risk?
Studies, approvals, and partner revenue may disappoint. Acquisitions and convertible bonds change capital needs and the share count; the June cash balance is not unchanged and available after the later transactions.
What is the overall assessment?
Growing pharmaceutical licensing revenue, but the share price already demands a great deal of success from new investments. Not attractive at the saved price.
Continue exploring this stock in your account
A free Marqora account gives you the detailed analysis with further evidence and lets you compare and save stocks. Your selected stock is kept when you sign in or register.
Open the full analysis in a free account →
Already have an account? Sign inSources used in the analysis
- Original source 1 · api-v4.fcsapi.com · Oct 21, 2026
- Original source 2 · data.sec.gov · Oct 21, 2026
- Original source 3 · data.sec.gov · Oct 21, 2026
- Original source 4 · investor.ligand.com · Aug 06, 2026
- Original source 5 · www.sec.gov · Sep 02, 2026
- Original source 6 · www.sec.gov · Sep 22, 2026
- Original source 7 · www.sec.gov · Sep 24, 2026